MedTech WebinarThursday 15st September at 1.00pm BST

Join a panel of MedTech CEOs and investors discuss the challenges in securing investment for accessing capital, including:

Martin FrostCEO

Cambridge Medical Robotics

Christoph RuedigPartner

Albion Ventures

Wolfgang RenckenCEO

Sphere Medical

Peter DinesInvestment Director, Head of Life

SciencesMercia Technologies

Meet the speakers

Martin FrostCEOCambridge Medical Robotics

Martin Frost has been involved in founding, financing and leading a wide range of technology companies in Cambridge for over 15 years, including Absolute Sensors (sold to Synaptics Inc.), Sensopad (sold to TT Electronics), Sphere Medical (now listed on the AIM market), and RedCloud Technology. Martin is a Director of Easdale Ventures and Omnisense, both of which he co-founded.A qualified Chartered Management Accountant, Martin had a mainstream finance career including with GEC-Marconi and the Simon Group before joining the Generics Group (now Sagentia) where he led the IPO in 2000 before being appointed Group CEO.

Meet the speakers

Christoph RuedigPartnerAlbion Ventures

Christoph joined Albion Ventures as an Investment Manager in October 2011 and now, as Partner, focuses on investments in healthcare and renewables. He initially practised as a radiologist, before spending 3 years at Bain & Company. In 2006, he joined 3i working for their Healthcare Venture Capital arm and most recently he has worked for General Electric's healthcare division, where he was responsible for mergers and acquisitions in the medical technology and healthcare IT sectors.

Meet the speakers

Wolfgang RenckenCEOSphere Medical

Dr Wolfgang Rencken is CEO of Sphere Medical having joined the Board in February 2014. He has extensive experience in the healthcare and medical diagnostic equipment industries. He has been responsible for the development and launch of many innovative medical devices and has a proven record of revenue and profit growth. His previous roles include CEO of MAQUET Cardiopulmonary AG, COO of Definiens AG, Vice President of Engineering in the Software Components and Workstations business unit of Siemens AG. Wolfgang has a doctorate in Engineering Science from the University of Oxford. He has written many scientific publications in the area of robotics and has authored a number of patents.

Meet the speakers

Peter DinesInvestment Director, Head of Life SciencesMercia Technologies

As a highly successful entrepreneur and investor, Peter brings 20 years’ experience in the healthcare sector, holding numerous directorships across a wide range of life sciences businesses. Over this period, Peter has been involved with a number of high profile turnarounds and exits within the sector, including the acquisition of Surgicraft’s loss making business where, as Managing Director, sales quadrupled within three years and the business was subsequently sold to ISIS Equity Partners. Other key healthcare positions held, both previously and currently, include Bridges Ventures, Cisiv, Diagnostic World, Spring Active and Newtech Ortho.

You will learn

• Defining MedTech subsectors; how do devices, diagnostics, data and platform tech companies fundamentally differ and what are the specific challenges to each in terms of securing investment?

• How can companies most effectively evidence the value of their products? What role should early investment partners be playing in this process?

• Is a focus on R&D investment to drive product innovation enough to secure finance, survive and grow as a MedTech?

• Where is the majority of the investment in the sector currently coming from? Is it simply a different group and type of investor that should be targeted?

You will learn

• What strategies should companies be considering to better protect themselves and become more investable propositions? E.g.

- Providing additional wraparound and bundled services- Focusing on bringing products to market offering strong value at low cost or developing an additional value around data and its analysis- Partnerships and collaborations with other innovators

• What are the most effective strategies for translating the generally agreed lower risk lower reward profile of MedTech, compared with Biotech, investment?

You will learn

• Are there alternative routes to capital (e.g. Family Offices, HNWs) that MedTech companies looking for funding should be exploring? What are the ways and means to connect with and explore this route to investment?

• Acquisitions; when should larger MedTechs be looking at acquisitions for growth and when should smaller companies be looking at a corporate sale as an exit?

• How important are, and will in future, accelerator and incubator programs for the next generation of MedTech innovation?

• What are your top 3 pieces of advice for accessing capital as a MedTech company?

You will learn

• Are there alternative routes to capital (e.g. Family Offices, HNWs) that MedTech companies looking for funding should be exploring? What are the ways and means to connect with and explore this route to investment?

• Acquisitions; when should larger MedTechs be looking at acquisitions for growth and when should smaller companies be looking at a corporate sale as an exit?

• How important are, and will in future, accelerator and incubator programs for the next generation of MedTech innovation?

• What are your top 3 pieces of advice for accessing capital as a MedTech company?